<DOC>
	<DOCNO>NCT00407953</DOCNO>
	<brief_summary>This post-marketing study conduct evaluate long-term safety effectiveness Prolieve Thermodilatation® System ( Prolieve® ) treatment Benign Prostatic Hyperplasia ( BPH ) . A secondary objective ass safety effectiveness re-treatment Prolieve® determine percent subject elect re-treated Prolieve® rather alternate therapy . This study follow subject treat Prolieve® 2 week , 3 month , yearly basis 5 year treatment . Both efficacy safety information collect follow-up visit . Procedural safety information collect treatment substantiate finding pivotal trial .</brief_summary>
	<brief_title>PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Diagnosed symptomatic BPH Peak urine flow rate &lt; 12 mL/sec void volume &gt; 125 mL AUA symptom score value &gt; =9 . Subjects whose pain response significantly decrease mean . Subject history illness surgery might confound result study `` impede successful completion trial '' . Subject history illness Prolieve® treatment may pose additional risk subject . Subject confirm suspected malignancy prostate Subject confirm suspected bladder cancer PSA &gt; 10 ng/mL Subject previous treatment prostate ( e.g. , surgery , balloon dilation , stent , laser , TUNA , Indigo prostatectomy ) and/or nonmetallic urogenital implant ( e.g. , penile prosthesis , artificial urinary sphincter ) Subject prostate weighing &lt; 20 &gt; 80 g. Subject previous pelvic irradiation radial pelvic surgery Subject large , obstructive middle lobe Previous rectal surgery ( hemorrhoidectomy ) history rectal disease Subject urethral stricture and/or bladder stone Active urinary tract infection Subject neurogenic bladder and/or sphincter abnormality due Parkinson 's , multiple sclerosis , cerebrovascular accident ( CVA ) , diabetes , disease process Residual bladder volume &gt; 250 mL measure ultrasound Compromised renal function ( i.e. , serum creatinine level 1.8 mg/dL ) Cardiac pacemaker metallic implant staple etc . pelvic/femoral area . Subject interested future fertility/fathering child Subject full urinary retention Subject bleed disorder liver dysfunction associate bleed disorder Subject prostatic urethra length &lt; 1.2 cm &gt; 5.5 cm . Concomitant medicate following : bladder antispasmodic within one week treatment , unless evidence subject drug dose least three month stable void pattern . The drug dose alter , discontinue entrance throughout study . 5alpha reductase inhibitor gonadotropin release hormonal analog . Alpha blocker , antidepressant , androgen , within one week treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>prostate</keyword>
	<keyword>BPH</keyword>
	<keyword>Prolieve</keyword>
	<keyword>AUA</keyword>
	<keyword>hyperthermia</keyword>
	<keyword>thermodilatation</keyword>
	<keyword>benign hyperplastic hyperplasia</keyword>
	<keyword>urology</keyword>
	<keyword>microwave therapy</keyword>
	<keyword>TUMT</keyword>
</DOC>